CN105579037A - 用黄嘌呤氧化酶抑制剂治疗的方法和含黄嘌呤氧化酶抑制剂的组合物 - Google Patents

用黄嘌呤氧化酶抑制剂治疗的方法和含黄嘌呤氧化酶抑制剂的组合物 Download PDF

Info

Publication number
CN105579037A
CN105579037A CN201480043009.9A CN201480043009A CN105579037A CN 105579037 A CN105579037 A CN 105579037A CN 201480043009 A CN201480043009 A CN 201480043009A CN 105579037 A CN105579037 A CN 105579037A
Authority
CN
China
Prior art keywords
dosage form
febustat
release dosage
gout
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480043009.9A
Other languages
English (en)
Chinese (zh)
Inventor
L.古纳瓦德哈纳
V.古普特
H.奈克
M.马耶
小松完尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teijin Pharma Ltd
Takeda Pharmaceuticals USA Inc
Original Assignee
Teijin Pharma Ltd
Takeda Pharmaceuticals North America Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd, Takeda Pharmaceuticals North America Inc filed Critical Teijin Pharma Ltd
Publication of CN105579037A publication Critical patent/CN105579037A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480043009.9A 2013-05-31 2014-05-30 用黄嘌呤氧化酶抑制剂治疗的方法和含黄嘌呤氧化酶抑制剂的组合物 Pending CN105579037A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361829759P 2013-05-31 2013-05-31
US61/829759 2013-05-31
US201361839609P 2013-06-26 2013-06-26
US61/839609 2013-06-26
PCT/US2014/040286 WO2014194226A2 (en) 2013-05-31 2014-05-30 Methods of treatment and compositions with xanthine oxidase inhibitors

Publications (1)

Publication Number Publication Date
CN105579037A true CN105579037A (zh) 2016-05-11

Family

ID=50983231

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480043009.9A Pending CN105579037A (zh) 2013-05-31 2014-05-30 用黄嘌呤氧化酶抑制剂治疗的方法和含黄嘌呤氧化酶抑制剂的组合物

Country Status (9)

Country Link
US (2) US20140357683A1 (enExample)
JP (2) JP2016520133A (enExample)
CN (1) CN105579037A (enExample)
CA (1) CA2913755A1 (enExample)
MX (1) MX2015016494A (enExample)
PH (1) PH12015502679A1 (enExample)
SG (2) SG11201509738RA (enExample)
TW (1) TW201536284A (enExample)
WO (1) WO2014194226A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017072699A1 (en) * 2015-10-28 2017-05-04 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of dimethyl fumarate
CN105769766B (zh) * 2016-03-24 2018-07-06 长沙佰顺生物科技有限公司 一种托匹司他纳米乳及其制备方法
JP7108384B2 (ja) * 2016-07-13 2022-07-28 日本ケミファ株式会社 ２－［３－シアノ－４－（２－メチルプロポキシ）フェニル］－４－メチルチアゾール－５－カルボン酸の口腔内崩壊錠
AU2017298142B2 (en) 2016-07-18 2021-11-11 Arthrosi Therapeutics, Inc. Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia
BR112021010708A2 (pt) 2018-12-06 2021-08-24 Arthrosi Therapeutics, Inc. Formas cristalinas de um composto para tratar ou prevenir gota ou hiperuricemia
KR20210102933A (ko) 2018-12-06 2021-08-20 아쓰로시 테라퓨틱스, 인크. 통풍 또는 고뇨산혈증의 치료 또는 예방 방법
CN113924145A (zh) * 2019-06-04 2022-01-11 日本化学药品株式会社 痛风或高尿酸血症的治疗药
CN117412746A (zh) * 2021-06-15 2024-01-16 株式会社Lg化学 包含1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸的药物组合物
AR126164A1 (es) * 2021-06-17 2023-09-27 Lg Chemical Ltd Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico
CN115252567A (zh) * 2022-07-08 2022-11-01 广西纯正堂制药有限公司 非布司他渗透泵缓释片及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090042887A1 (en) * 2007-01-19 2009-02-12 Tap Pharmaceutical Products, Inc. Methods for Preventing or Reducing the Number of Gout Flares Using Xanthine Oxidoreductase Inhibitors and Anti-Inflammatory Agents
US20110311620A1 (en) * 2010-06-16 2011-12-22 Takeda Pharmaceuticals North America, Inc. Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US5286497A (en) 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5573776A (en) 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
US5544163A (en) 1994-03-08 1996-08-06 Excel, Inc. Expandable telecommunications system
SI1488790T1 (sl) 2002-03-28 2014-09-30 Teijin Pharma Limited Trden pripravek, ki vsebuje eno samo kristalno a-obliko derivata tiazolkarboksilne kisline
PL1757610T3 (pl) 2004-06-14 2011-10-31 Nippon Chemiphar Co Skondensowana pochodna pirymidyny oraz inhibitor oksydazy ksantynowej
US7816558B2 (en) * 2005-10-07 2010-10-19 Astellas Pharma Inc. Triarylcarboxylic acid derivative
HRP20130846T1 (hr) * 2009-03-31 2013-11-22 Kissei Pharmaceutical Co., Ltd. Derivati indolizina i njihova uporaba u medicinske svrhe
CN101773498B (zh) * 2009-12-30 2012-06-20 青岛黄海制药有限责任公司 一种含有非布司他的口服缓控释制剂的制备方法
WO2011158870A1 (ja) 2010-06-16 2011-12-22 帝人ファーマ株式会社 放出制御型の有核錠剤
CN102641255A (zh) * 2012-05-08 2012-08-22 南方医科大学 一种治疗痛风的非布索坦渗透泵控释片及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090042887A1 (en) * 2007-01-19 2009-02-12 Tap Pharmaceutical Products, Inc. Methods for Preventing or Reducing the Number of Gout Flares Using Xanthine Oxidoreductase Inhibitors and Anti-Inflammatory Agents
US20110311620A1 (en) * 2010-06-16 2011-12-22 Takeda Pharmaceuticals North America, Inc. Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
WO2011159745A1 (en) * 2010-06-16 2011-12-22 Takeda Pharmaceuticals North America, Inc. Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors

Also Published As

Publication number Publication date
WO2014194226A3 (en) 2015-05-14
JP2016520133A (ja) 2016-07-11
SG10201709955PA (en) 2018-01-30
US20140357683A1 (en) 2014-12-04
CA2913755A1 (en) 2014-12-04
SG11201509738RA (en) 2015-12-30
WO2014194226A2 (en) 2014-12-04
JP2019108356A (ja) 2019-07-04
TW201536284A (zh) 2015-10-01
MX2015016494A (es) 2016-11-18
US20180311217A1 (en) 2018-11-01
PH12015502679A1 (en) 2016-03-07

Similar Documents

Publication Publication Date Title
CN105579037A (zh) 用黄嘌呤氧化酶抑制剂治疗的方法和含黄嘌呤氧化酶抑制剂的组合物
US8501766B2 (en) Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
US20250312323A1 (en) Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
Khosravan et al. The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase
CN108012527A (zh) 苯并咪唑衍生物用于夜间酸突破的用途
JP2022191405A (ja) 結節性痒疹を治療するための抗掻痒剤
CN102600146B (zh) 一种盐酸乐卡地平和氯沙坦钾复方制剂及其制备方法
EP4335438A1 (en) Combination therapy with vildagliptin and metformin
Korth-Bradley et al. Comparative bioavailability study of single-dose film-coated and sugar-coated ethionamide tablets in healthy volunteers
EP4360631A1 (en) Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid
US20240408086A1 (en) Use of luvadaxistat for the treatment of cognitive impairment
HK1224561A1 (en) Methods of treatment and compositions with xanthine oxidase inhibitors
US9889125B2 (en) Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy
CA3219829A1 (en) Method of treating essential tremor
US20220117916A1 (en) Combination Products to Mitigate the Risk of Non-Benzodiazepine Benzodiazepine Agonist Adverse Reaction and Overdose
Tang et al. Terazosin versus Alfuzosin in Treatment of Acute Urinary Retention in Patients with Benign Prostatic Hypertroph
TW202342042A (zh) 用於治療亨丁頓舞蹈症的片劑及其製備方法
EP3328386A1 (en) A prolonged release dosage form comprising oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof in the treatment of bladder pain syndrome (bps)
HK1160586A (en) Durable treatment with 4-aminopyridine in patients with demyelination

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1224561

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160511

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1224561

Country of ref document: HK